US20210349110A1 - Method for providing information on diagnosis or prognostic measurement of histological severity of nonalcoholic fatty liver disease - Google Patents

Method for providing information on diagnosis or prognostic measurement of histological severity of nonalcoholic fatty liver disease Download PDF

Info

Publication number
US20210349110A1
US20210349110A1 US17/283,058 US201917283058A US2021349110A1 US 20210349110 A1 US20210349110 A1 US 20210349110A1 US 201917283058 A US201917283058 A US 201917283058A US 2021349110 A1 US2021349110 A1 US 2021349110A1
Authority
US
United States
Prior art keywords
obese
nafld
severity
fatty liver
nonalcoholic fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/283,058
Inventor
Won Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seoul National University Hospital
Original Assignee
Seoul National University Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seoul National University Hospital filed Critical Seoul National University Hospital
Assigned to SEOUL NATIONAL UNIVERSITY HOSPITAL reassignment SEOUL NATIONAL UNIVERSITY HOSPITAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KIM, WON
Publication of US20210349110A1 publication Critical patent/US20210349110A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present disclosure relates to a method for providing information on diagnosis or prognosis determination of the histological severity of nonalcoholic fatty liver disease and, more specifically, to a method for identifying the increase or decrease of the risk associated with the severity of nonalcoholic fatty liver disease by measuring the levels of saturated sphingomyelins.
  • Nonalcoholic fatty liver disease is caused by the abnormal accumulation of hepatic triglycerides (TGs), which is referred to as liver steatosis, and may occasionally progress to nonalcoholic steatohepatitis (NASH) and related fibrosis.
  • TGs hepatic triglycerides
  • NASH nonalcoholic steatohepatitis
  • the excessive accumulation of hepatic TGs is known to initiate NAFLD, the specific types and amounts of lipid classes accumulated in steatotic livers and the impact of lipid alterations on NAFLD progression have not been completely characterized. Since most lipids have important biological activities, the lipid profiling approach offers useful information to help the understanding of NAFLD pathogenesis.
  • Obesity and insulin resistance are major risk factors for metabolic syndromes, such as NAFLD and type 2 diabetes.
  • NAFLD body mass index
  • a considerable number of NAFLD patients have a relatively low body mass index (BMI ⁇ 25 kg/m 2 ) and less insulin resistance. Since NAFLD is closely associated with obesity, previous metabolomics studies have focused on obese Caucasian adult males with a BMI ⁇ 30 kg/m 2 .
  • the present inventors verified that the histological severity can be diagnosed by measuring the levels of sphingomyelins (SMs) in sera of non-obese nonalcoholic fatty liver disease (NAFLD) patients.
  • SMs sphingomyelins
  • an aspect of the present disclosure is to provide a method for providing information on diagnosis or prognosis determination of the histological severity of nonalcoholic fatty liver disease, the method including a measurement step of measuring the level of a sphingomyelin in a biological sample isolated from a subject.
  • Another aspect of the present disclosure is to provide use of a sphingomyelin measurement value for providing information of diagnosis or prognosis determination of the histological severity of nonalcoholic fatty liver disease.
  • the present disclosure is directed to a method for providing information on diagnosis or prognosis determination of the histological severity of nonalcoholic fatty liver disease (NAFLD), and the method according to the present disclosure indicates that the increase or decrease of the risk associated with the severity of nonalcoholic fatty liver disease (NAFLD) can be identified by measuring the level of a sphingomyelin (SM) in the serum of a patient.
  • NAFLD histological severity of nonalcoholic fatty liver disease
  • the present inventors derived that the risk associated with the severity of nonalcoholic fatty liver disease increases when the level of a saturated sphingomyelin is at least 1.3-fold compared with a normal serum.
  • An aspect of the present disclosure is to provide a method for providing information on diagnosis or prognosis determination of histological severity of nonalcoholic fatty liver disease (NAFLD), the method including a measurement step of measuring the level of a sphingomyelin (SM) in a biological sample isolated from a subject.
  • NAFLD nonalcoholic fatty liver disease
  • the sphingomyelin may be a saturated sphingomyelin.
  • the method may further include a risk determination step of determining that the risk associated with the severity of nonalcoholic fatty liver disease of the subject increases when the level of the saturated sphingomyelin in the measurement step is at least 1.3-fold compared with a normal control sample.
  • the subject was classified as non-obese when the body mass index of the subject was less than 25 and as obese when the body mass index of the subject was 25 or more.
  • the subject may have a body mass index (BMI) of less than 25.
  • BMI body mass index
  • the subject may be an Asian.
  • the reason is that a study that presents blood metabolite profiles of Western non-obese NAFLD patients has been disclosed, but the WHO recommended that the WHO BMI standards for the Asian population need to be adopted differently from the international classifications.
  • Asian refers to any person having origins in any original peoples of China, Mongolia, Taiwan, Singapore, Korea, Japan, Vietnam, Cambodia, Laos, Burma, Thailand, Malaysia, Indonesia, and Philippines.
  • the biological sample may be a serum or plasma.
  • the level of a saturated sphingomyelin is measured in the serum isolated from a non-obese Asian patient with a body mass index of less than 25 and the measured sphingomyelin level is increased by at least 1.3-fold compared with a normal control sample, it is determined that the risk associated with the severity of nonalcoholic fatty liver disease increases.
  • the present disclosure is directed to a method for providing information on diagnosis or prognosis determination of the histological severity of nonalcoholic fatty liver disease, and the risk associated with the severity of nonalcoholic fatty liver disease is considered to increase when the level of a sphingomyelin is at least 1.3-fold compared with a normal control, and thus the sphingomyelin level can be effectively used in the diagnosis or prognosis determination of the severity.
  • FIG. 1A is a graph showing fold changes of lipid species in nonalcoholic fatty liver (NAFL)/no-nonalcoholic fatty disease (no-NAFLD) for non-obese patients.
  • NAFL nonalcoholic fatty liver
  • no-NAFLD nonalcoholic fatty disease
  • FIG. 1B is a graph showing fold changes of lipid species in nonalcoholic steatohepatitis (NASH)/NAFL for non-obese patients.
  • NASH nonalcoholic steatohepatitis
  • FIG. 1C is a graph showing fold changes of lipid species in NAFL/no-NAFLD for obese patients.
  • FIG. 1D is a graph showing fold changes of lipid species in NASH/NAFL for obese patients.
  • FIG. 2A provides graphs showing changes in diacylglycerol (DAG) levels according to the acyl chain length and the degree of desaturation.
  • DAG diacylglycerol
  • FIG. 2B provides graphs showing changes in triacylglycerol (TAG) levels according to the acyl chain length and the degree of desaturation.
  • TAG triacylglycerol
  • FIG. 3 provides graphs showing changes in sphingomyelin (SM) levels in NAFL/no-NAFLD and NASH/NAFL for the non-obese and obese groups.
  • SM sphingomyelin
  • FIG. 4 provides Spearman's correlation heat maps showing the correlation of SM levels with metabolic risk factors and liver histological severity.
  • FIG. 5A is a graph showing saturated sphingomyelin levels according to grades of steatosis in the non-obese group.
  • FIG. 5B is a graph showing saturated sphingomyelin levels according to grades of lobular inflammation in the non-obese group.
  • FIG. 5C is a graph showing saturated sphingomyelin levels according to grades of ballooning in the non-obese group.
  • FIG. 5D is a graph showing saturated sphingomyelin levels according to grades of fibrosis in the non-obese group.
  • FIG. 6A provides graphs showing the liver histological predictive ability of steatosis using the saturated sphingomyelin composition.
  • FIG. 6B provides graphs showing the liver histological predictive ability of lobular inflammation using the saturated sphingomyelin composition.
  • FIG. 6C provides graphs showing the liver histological predictive ability of ballooning using the saturated sphingomyelin composition.
  • FIG. 7 provides graphs showing the histological severity diagnostic performance of NAFLD by combinations of SM d36:0, SM d38:0, and SM d40:0 and aspartate transaminase (AST), alanine transaminase (ALT), and gamma-glutamyl transferase (GGT) in the non-obese (blue curve) and obese (red curve) groups.
  • AST aspartate transaminase
  • ALT alanine transaminase
  • GTT gamma-glutamyl transferase
  • the present disclosure is directed to a method for providing information on diagnosis or prognosis determination of the histological severity of nonalcoholic fatty liver disease (NAFLD), the method including a measurement step of measuring the level of a sphingomyelin (SM) in a biological sample isolated from a subject.
  • NAFLD nonalcoholic fatty liver disease
  • DM non-obese
  • MS metabolic syndrome
  • hsCRP high sensitivity C-reactive protein
  • FPG fasting plasma glucose
  • TC total cholesterol
  • HDL-C high density lipoprotein cholesterol
  • serum aspartate aminotransferase AST
  • alanine aminotransferase ALT
  • gamma-glutamyl transferase GTT
  • no-NAFLD group had no clinical, biochemical, radiological, or histological evidence of fatty liver.
  • 82 had NAFLD and 48 were controls.
  • 213 subjects had NAFLD and 18 were controls.
  • non-obese/no-NAFLD Based on BMI and liver histology findings (no-NAFLD, NAFL, and NASH), study subjects were classified into six groups: non-obese/no-NAFLD; non-obese/NAFL; non-obese/NASH; obese/no-NAFLD; obese/NAFL; and obese/NASH.
  • the subjects with biopsy-proven NAFLD and BMI of less than 25 kg/m 2 (“Boramae NAFLD cohort” (NCT 02206841)) were defined as non-obese NAFLD subjects. Controls were determined through liver biopsy during the evaluation on a living-donor liver transplant and confirmed to have no NAFLD through characterization of a solid liver mass suspected of liver adenoma or focal nodular hyperplasia based on abdominal image examination.
  • NAFLD was defined as the presence of 5% or more of macrovesicular steatosis identified via histological examination. NASH was diagnosed based on histological criteria of NASH-clinical research network (CRN): an overall pattern of histological hepatic injury consisting of steatosis, lobular inflammation, ballooning, or fibrosis was graded according to the NAFLD activity storing system.
  • CNN NASH-clinical research network
  • the visceral adipose tissue (VAT) area was measured for quantification of visceral adipose amounts.
  • Systemic insulin resistance (HOMA-IR) and ⁇ -cell function (HOMA- ⁇ ) were evaluated using HOMA-B, and the insulin resistance in adipose tissue (adipo-IR) was also calculated.
  • the metabolic syndrome was defined by the national cholesterol education program adult treatment panel III (NCEP ATP III) criteria.
  • HMDB human metabolome database
  • METLIN https://metlin.scripps.edu
  • LIPID MAPS www.lipidmaps.org
  • HPLC high-performance liquid chromatography
  • MS mass spectrometry
  • UPLC/QTOF-MS ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry
  • Lipidomic profiles of all lipid classes include: free fatty acids (FFA); glycerolipids (diacylglycerol (DAG) and triacylglycerol (TAG)); glycerophospholipids (lysophosphatidic acid (LPA), lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylinositol (PI); and sphingolipids (ceramide (Cer) and SM). Fold changes of lipid species in NAFL vs no-NAFLD and NASH vs NAFL for non-obese and obese patients are presented in FIG. 1 .
  • Fold changes of lipid species in NAFL vs no-NAFLD and NASH vs NAFL for non-obese and obese patients are presented in FIG. 1 .
  • lipid species such as DAG, TAG, and SM, showed characteristic change patterns according to the histological severity of NAFLD in non-obese and obese adult NAFLD patients.
  • the ratios of blood glycerolipid levels (concentrations) in NAFL to normal liver (no-NAFLD) were significantly higher, but the ratios in NASH to NAFL showed no significant differences.
  • the ratios of blood SM levels in NAFL to normal liver (no-NAFLD) and the ratios of blood SM levels in NASH to NAFL were significantly high only in the non-obese group, but showed no significant differences in the obese group.
  • each serum sample was mixed with 500 ⁇ L of chloroform/methanol (2:1, v/v). After centrifugation at 13,000 rpm for 20 min at 4° C., 300 ⁇ L of the lower lipid phase was collected, and the solvents were removed under a gentle nitrogen stream at room temperature. The dried extracts were reconstituted in 250 ⁇ L of an isopropanol/acetonitrile/water mixture (2:1:1, v/v/v).
  • the column oven and auto-sampler temperatures were maintained at 40° C. and 4° C., respectively.
  • the samples were eluted and separated using an Acquity UPLC BEH C18 column (2.1 ⁇ m ⁇ 1.7 mm particles, Waters).
  • the LC mobile phase was composed of 10 mM ammonium acetate in an acetonitrile/water mixture (4:6, v/v) (solvent A) and 10 mM ammonium acetate in an acetonitrile/isopropanol mixture (1:9, v/v) (solvent B).
  • Gradient elution began with 40% B, increased to 65% B after 5 min, and then continuously increased until the composition of B was 99% by 10 min.
  • composition was held at 99% B for 2 min.
  • resultant composition was returned to initial conditions after 17 min and was finally maintained for 3 min until equilibration.
  • the flow rates were set to 350 ⁇ L/min. Five microliters of lipid extracts were injected into the UPLC/QTOF-MS system.
  • ion spray voltage of 5500 V was used for operation: ion spray voltage of 5500 V, source temperature of 500° C., a nebulizer pressure of 50 psi, a drying gas pressure of 60 psi, curtain gas of 30 psi, declustering potential of 90 V, and information-dependent acquisition (IDA) was used to acquire MS/MS spectra for ions.
  • the collision energy and collision energy spread were adjusted as 40 V and 15 V, respectively.
  • the mass accuracy was maintained with an automated calibrant delivery system (AB Sciex) interfaced with the DuoSpray ion source.
  • Lipid metabolites were identified according to available information (accurate mass, fragment ions, and/or retention time) that matched data from online databases (DBs; HMDB, METLIN, LIPID MAPS) and standard compounds.
  • Distinctive increases in glycerolipids including DAG and TAG species were observed in both the non-obese and obese groups, with a stepwise increase from NAFL to NASH.
  • the differences in DAG and TAG levels with acyl chain lengths, degrees of desaturation, fold changes, and p-values were visualized using bubble plots.
  • the bubble plots illustrated the correlations among the chain length, degree of desaturation, fold change, and p-value of DAG and TAG through the comparison of histological subgroups.
  • the y-axis represents the degree of desaturation, and the position of the bubbles relative to the x-axis corresponds to the chain length.
  • the color of the bubbles indicates the fold change, and the size of the bubbles represents p-values that were obtained in the Mann-Whitney U-test with the Bonferroni correction.
  • the changes in DAG levels showed distinctive patterns among various histological subgroups.
  • the levels of DAGs with relatively short chains and low degrees of desaturation statistically increased in NAFL vs NAFLD, regardless of obesity.
  • the levels of DAGs with long chains and high degrees of desaturation significantly decreased in NASH vs NAFL for the obese group.
  • the glycerolipids including DAG and TAG species exhibited distinctive change patterns that were affected by the length and desaturation degree of acyl chains. Moreover, the pattern of glycerolipid changes based on the histological severity was different between the non-obese and obese groups. Resultantly, the fold changes of circulating DAGs and TAGs classified based on histological severity were greater in obese NAFLD subjects than non-obese NAFLD patients.
  • the ratios of blood glycerolipid levels (concentrations) in NAFL to normal liver (no-NAFLD) were significantly higher in the obese group compared with the non-obese group, but the ratios of levels in NASH to NAFL showed no great differences.
  • the levels of saturated SMs including SM d36:0, SM d38:0, and SM d40:0, markedly increased by at least 1.3-fold in the NAFL/no-NAFLD group in the non-obese group.
  • the levels of SMs containing a long-chain length of greater than 42 carbons decreased in NAFL/no-NAFLD group, regardless of obesity.
  • the levels of saturated SMs such as SM d34:0, SM d36:0, SM d38:0, and SM d40:0, significantly increased in NASH/NAFL, but were not significant in NAFL/no-NAFLD.
  • VAT visceral adipose tissue
  • HbA1c glycated haemoglobin
  • adipo-IR insulin resistance in adipose tissue
  • HOMA-IR homeostasis model assessment of insulin resistance
  • HOMA- ⁇ homeostasis model assessment of ⁇ -cell function
  • LI lobular inflammation
  • the levels of SM d36:0, SM d38:0, and SM d40:0 were significantly positively correlated with the VAT area, adipo-IR, and HOMA-IR in the non-obese group and were positively correlated with adipo-IR and HOMA-IR in the obese group.
  • saturated SM levels were strongly correlated with the severity of steatosis, ballooning, and lobular inflammation in the non-obese group.
  • only the steatosis was positively correlated with saturated lipid levels and amounts in the obese group.
  • SM d36:0, SM d38:0, and SM d40:0 were altered by the presence and severity of steatosis and lobular inflammation.
  • Data are expressed as the means ⁇ standard deviation. Statistical significance is indicated with asterisks (Jonckheere-Terpstra test, *p ⁇ 0.05, ** p ⁇ 0.01, and *** p ⁇ 0.001).
  • the levels of saturated SMs markedly increased depending on the severity of steatosis, lobular inflammation, ballooning, and fibrosis according to grades thereof, especially in the non-obese patients.
  • the saturated SM levels in the obese patients showed no stepwise increase with respect to the measurement of the histological severity of NAFLD except for the measurement of grades of steatosis.
  • the fibrosis stage also had no stepwise association with the saturated SM levels regardless of obesity.
  • the saturated SM levels were further useful in improving diagnostic performance of NAFL and NASH in non-obese patients rather than obese NAFL and NASH, thereby preventing liver biopsy especially unnecessary for non-obese adult NAFLD patients.
  • AUROCs with 95% CI were classified into the non-obese and obese groups and presented in Table 3 and FIG. 6 .
  • the AUROCs for steatosis 1, 2, and 3 were 0.644, 0.789, and 0.868, respectively.
  • the AUROCs for S1, S2, and S3 were 0.679, 0.670, and 0.809, respectively.
  • the AUROCs for lobular inflammation were 0.613 (score 1) and 0.812 (score 2), and in the obese group, the AUROCs were 0.561 and 0.666.
  • the AUROCs for ballooning were 0.726 (score 1) and 0.793 (score 2).
  • the AUROCs for scores 1 and 2 were 0.613 and 0.643, respectively.
  • the ROC curves based on the histological severity in the non-obese group showed significantly high AUROCs compared with the obese group.
  • the AUROCs were adjusted using combinations of AST, ALT, and GGT levels (model 1) or combinations of saturated SM levels (SM d36:0, SM d38:0, and SM d40:0) with AST, ALT, and GGT levels (model 2). P-values for pairwise comparison of AUROCs were provided using DeLong test.
  • the diagnostic performance for distinguishing NASH from NAFL was significantly improved in the non-obese group.
  • the present disclosure relates to a method for providing information on diagnosis or prognosis determination of the histological severity of nonalcoholic fatty liver disease and, more specifically, to a method for identifying the increase or decrease of the risk associated with the severity of nonalcoholic fatty liver disease by measuring the levels of saturated sphingomyelins.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a method for providing information on a diagnosis or prognostic measurement of the histological severity of nonalcoholic fatty liver disease. Since the risk associated with the severity of nonalcoholic fatty liver disease can be considered to have increased when the content of sphingomyelin is at least 1.3 times higher than in a normal control group, the present invention can be effectively used for the diagnosis or prognostic measurement of severity.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a national phase application of PCT Application No. PCT/KR2019/014084, filed on Oct. 24, 2019, which claims the benefit and priority to Korean Patent Application No. 10-2018-0129190, filed on Oct. 26, 2018. The entire disclosures of the applications identified in this paragraph are incorporated herein by references.
    • TECHNICAL FIELD
  • The present disclosure was made with the support of the Ministry of Health and Welfare of the Republic of Korea, under Project No. 1465025699, which was conducted in the research project named “Analysis of Microbiomes and Serum Metabolites in Faces Through Hepatic histopathological findings in Large-Scale Korean Non-Alcoholic Fatty Liver Prospective Cohort” in the research program entitled “Disease Overcoming Technology Development”, by Seoul Metropolitan Government Seoul National University Boramae Medical Center, under the management of the Korean Health Industry Development Institute, 1 Jan. 2018 to 31 Dec. 2018.
  • The present disclosure relates to a method for providing information on diagnosis or prognosis determination of the histological severity of nonalcoholic fatty liver disease and, more specifically, to a method for identifying the increase or decrease of the risk associated with the severity of nonalcoholic fatty liver disease by measuring the levels of saturated sphingomyelins.
    • BACKGROUND ART
  • Nonalcoholic fatty liver disease (NAFLD) is caused by the abnormal accumulation of hepatic triglycerides (TGs), which is referred to as liver steatosis, and may occasionally progress to nonalcoholic steatohepatitis (NASH) and related fibrosis. Although the excessive accumulation of hepatic TGs is known to initiate NAFLD, the specific types and amounts of lipid classes accumulated in steatotic livers and the impact of lipid alterations on NAFLD progression have not been completely characterized. Since most lipids have important biological activities, the lipid profiling approach offers useful information to help the understanding of NAFLD pathogenesis.
  • Obesity and insulin resistance are major risk factors for metabolic syndromes, such as NAFLD and type 2 diabetes. However, a considerable number of NAFLD patients have a relatively low body mass index (BMI<25 kg/m2) and less insulin resistance. Since NAFLD is closely associated with obesity, previous metabolomics studies have focused on obese Caucasian adult males with a BMI≥30 kg/m2.
  • However, thin NAFLD patients with healthier metabolic profiles still showed increased total mortality compared with NAFLD patients of overweight or obese groups. Therefore, a better understanding of a metabolic difference between non-obese patients and obese patients both with NAFLD is decisively important in the development of precision medicine and customized therapies based on the various phenotypes and progression levels of NAFLD.
  • There has been a study that suggests blood metabolite profiles of Western non-obese NAFLD patients with BMI<30 kg/m2, but the WHO expert consultation (WHO) recommended that the WHO BMI standards for Asian populations need to be adopted differently from the international classifications.
  • Although there has been found distinct differences in serum metabolites between non-obese (BMI≤25 kg/kg/m2) and obese (BMI≥30 kg/m2) subjects, the differences between nonalcoholic fatty liver (NAFL) and NASH, which have been histologically confirmed in obese and non-obese NAFLD subjects, need to be further examined.
  • Therefore, blood lipid distribution variations according to the histological severity of NAFLD need to be comprehensively investigated by using sera obtained from biopsy-proven non-obese and obese Asian adult patients.
    • SUMMARY Technical Problem
  • The present inventors verified that the histological severity can be diagnosed by measuring the levels of sphingomyelins (SMs) in sera of non-obese nonalcoholic fatty liver disease (NAFLD) patients.
  • Accordingly, an aspect of the present disclosure is to provide a method for providing information on diagnosis or prognosis determination of the histological severity of nonalcoholic fatty liver disease, the method including a measurement step of measuring the level of a sphingomyelin in a biological sample isolated from a subject.
  • Another aspect of the present disclosure is to provide use of a sphingomyelin measurement value for providing information of diagnosis or prognosis determination of the histological severity of nonalcoholic fatty liver disease.
    • Technical Solution
  • The present disclosure is directed to a method for providing information on diagnosis or prognosis determination of the histological severity of nonalcoholic fatty liver disease (NAFLD), and the method according to the present disclosure indicates that the increase or decrease of the risk associated with the severity of nonalcoholic fatty liver disease (NAFLD) can be identified by measuring the level of a sphingomyelin (SM) in the serum of a patient.
  • The present inventors derived that the risk associated with the severity of nonalcoholic fatty liver disease increases when the level of a saturated sphingomyelin is at least 1.3-fold compared with a normal serum.
  • Hereinafter, the present disclosure will be described in more detail.
  • An aspect of the present disclosure is to provide a method for providing information on diagnosis or prognosis determination of histological severity of nonalcoholic fatty liver disease (NAFLD), the method including a measurement step of measuring the level of a sphingomyelin (SM) in a biological sample isolated from a subject.
  • The sphingomyelin may be a saturated sphingomyelin.
  • The method may further include a risk determination step of determining that the risk associated with the severity of nonalcoholic fatty liver disease of the subject increases when the level of the saturated sphingomyelin in the measurement step is at least 1.3-fold compared with a normal control sample.
  • Herein, the subject was classified as non-obese when the body mass index of the subject was less than 25 and as obese when the body mass index of the subject was 25 or more.
  • In the present disclosure, the subject may have a body mass index (BMI) of less than 25. The reason is that specific saturated SMs play a key role in not only the occurrence of nonalcoholic fatty acid but also the progression to NASH in a non-obese group with a body mass index of less than 25, but these features cannot be confirmed in an obese group with a body mass index of 25 or more.
  • In the present disclosure, the subject may be an Asian. The reason is that a study that presents blood metabolite profiles of Western non-obese NAFLD patients has been disclosed, but the WHO recommended that the WHO BMI standards for the Asian population need to be adopted differently from the international classifications.
  • In the present disclosure, “Asian” refers to any person having origins in any original peoples of China, Mongolia, Taiwan, Singapore, Korea, Japan, Vietnam, Cambodia, Laos, Burma, Thailand, Malaysia, Indonesia, and Philippines.
  • In the present disclosure, the biological sample may be a serum or plasma.
  • In an embodiment of the present disclosure, when the level of a saturated sphingomyelin is measured in the serum isolated from a non-obese Asian patient with a body mass index of less than 25 and the measured sphingomyelin level is increased by at least 1.3-fold compared with a normal control sample, it is determined that the risk associated with the severity of nonalcoholic fatty liver disease increases.
    • Advantageous Effects
  • The present disclosure is directed to a method for providing information on diagnosis or prognosis determination of the histological severity of nonalcoholic fatty liver disease, and the risk associated with the severity of nonalcoholic fatty liver disease is considered to increase when the level of a sphingomyelin is at least 1.3-fold compared with a normal control, and thus the sphingomyelin level can be effectively used in the diagnosis or prognosis determination of the severity.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A is a graph showing fold changes of lipid species in nonalcoholic fatty liver (NAFL)/no-nonalcoholic fatty disease (no-NAFLD) for non-obese patients.
  • FIG. 1B is a graph showing fold changes of lipid species in nonalcoholic steatohepatitis (NASH)/NAFL for non-obese patients.
  • FIG. 1C is a graph showing fold changes of lipid species in NAFL/no-NAFLD for obese patients.
  • FIG. 1D is a graph showing fold changes of lipid species in NASH/NAFL for obese patients.
  • FIG. 2A provides graphs showing changes in diacylglycerol (DAG) levels according to the acyl chain length and the degree of desaturation.
  • FIG. 2B provides graphs showing changes in triacylglycerol (TAG) levels according to the acyl chain length and the degree of desaturation.
  • FIG. 3 provides graphs showing changes in sphingomyelin (SM) levels in NAFL/no-NAFLD and NASH/NAFL for the non-obese and obese groups.
  • FIG. 4 provides Spearman's correlation heat maps showing the correlation of SM levels with metabolic risk factors and liver histological severity.
  • FIG. 5A is a graph showing saturated sphingomyelin levels according to grades of steatosis in the non-obese group.
  • FIG. 5B is a graph showing saturated sphingomyelin levels according to grades of lobular inflammation in the non-obese group.
  • FIG. 5C is a graph showing saturated sphingomyelin levels according to grades of ballooning in the non-obese group.
  • FIG. 5D is a graph showing saturated sphingomyelin levels according to grades of fibrosis in the non-obese group.
  • FIG. 6A provides graphs showing the liver histological predictive ability of steatosis using the saturated sphingomyelin composition.
  • FIG. 6B provides graphs showing the liver histological predictive ability of lobular inflammation using the saturated sphingomyelin composition.
  • FIG. 6C provides graphs showing the liver histological predictive ability of ballooning using the saturated sphingomyelin composition.
  • FIG. 7 provides graphs showing the histological severity diagnostic performance of NAFLD by combinations of SM d36:0, SM d38:0, and SM d40:0 and aspartate transaminase (AST), alanine transaminase (ALT), and gamma-glutamyl transferase (GGT) in the non-obese (blue curve) and obese (red curve) groups.
    •  BEST MODE FOR CARRYING OUT THE INVENTION
  • The present disclosure is directed to a method for providing information on diagnosis or prognosis determination of the histological severity of nonalcoholic fatty liver disease (NAFLD), the method including a measurement step of measuring the level of a sphingomyelin (SM) in a biological sample isolated from a subject.
    • DETAILED DESCRIPTION
  • Hereinafter, the present disclosure will be described in more detail by the following examples. However, these examples are used only for illustration, and the scope of the present disclosure is not limited by these examples.
    • Example 1: Basic Characteristics of Study Participants
  • As shown in Tables 1 and 2, subjects were classified according to their BMI as non-obese (<25) and obese (≥25) (diabetes mellitus (DM), metabolic syndrome (MS), high sensitivity C-reactive protein (hsCRP), fasting plasma glucose (FPG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C)).
  • TABLE 1
    Non-obese (BMI < 25)
    No-NAFLD NAFL NASH
    Parameters (n = 48) (n = 51) (n = 31) P-value
    Age (years) 53.3 ± 11.9 58.6 ± 12.2 61.0 ± 9.8  0.011
    Male, n (%) 18 (37.5) 27 (52.9) 10 (32.3) 0.853
    BMI (kg/m2) 22.6 ± 1.6  23.2 ± 1.3  23.6 ± 0.9  0.034
    Waist circumference (cm) 81.2 ± 5.5  83.1 ± 4.6  84.6 ± 3.3  0.04
    VAT (cm2) 83.8 ± 35.2 110.4 ± 34.2  120.5 ± 36.7  <0.001***
    DM, N (%)  9 (18.8) 25 (49.0) 16 (51.6) <0.001***
    MS, N (%) 16 (33.3) 29 (56.9) 25 (80.6) 0.004
    Adipo-IR 5.1 ± 4.3 6.4 ± 4.1 9.3 ± 6.4 <0.001*
    HOMA-IR 2.4 ± 1.1 3.2 ± 2.1 4.1 ± 2.2 <0.001*
    HOMA-β 96.2 ± 52.3 83.1 ± 42.4 119.8 ± 88.0  0.169
    HbA1c 5.7 ± 0.6 6.6 ± 1.4 6.6 ± 1.0 <0.001***
    hsCRP (mg/dL) 0.18 ± 0.36 0.18 ± 0.35 0.30 ± 0.45 <0.001*†
    FPG (mg/dL) 103.2 ± 20.3  119.3 ± 35.9  117.3 ± 33.9  0.009*
    FFA (mg/dL) 552.7 ± 279.8 608.7 ± 228.6 674.7 ± 301  0.074
    TC (mg/dL) 184.4 ± 37.3  182.9 ± 43.4  175.7 ± 40.3  0.793
    TG (mg/dL)  117 ± 64.6 153.1 ± 64.4  167.3 ± 74.9  <0.001**
    HDL-C (mg/dL) 52.3 ± 12.8 46.1 ± 14.9 42.4 ± 10.4 0.002*
    AST (U/L) 27.5 ± 19.8 30.8 ± 17.6 55.7 ± 39.4 <0.001*†††
    ALT (U/L) 24.3 ± 15.3 37.6 ± 26.6 62.2 ± 49.7 <0.001**
    GGT (U/L) 38.9 ± 40.1 44.2 ± 58.8 102.8 ± 222.4 0.002††
  • TABLE 2
    Obese (BMI ≥ 25)
    No-NAFLD NAFL NASH
    Parameters (n = 18) (n = 106) (n= 107) P-value
    Age (years) 55.8 ± 9.1  49.5 ± 14.5 51.2 ± 16.1 0.26
    Male, n (%) 7 (38.9) 65 (61.3) 48 (44.9) 0.272†
    BMI (kg/m2) 27.8 ± 2.1  28.1 ± 2.2  29.6 ± 3.2  0.002††
    Waist circumference (cm) 95.5 ± 5.1  94.7 ± 6.1  98.8 ± 9.5  0.014†
    VAT (cm2) 129.9 ± 44.5  137.4 ± 42.2  154.4 ± 57.2  0.015†
    DM, N (%) 4 (22.2) 35 (33.0) 53 (49.5) 0.004†
    MS, N (%) 8 (44.4) 78 (73.6) 89 (83.2) 0.06
    Adipo-IR 6.0 ± 3.3 8.2 ± 4.9 14.1 ± 11.1 <0.001†††
    HOMA-IR 2.2 ± 0.7 3.8 ± 2.3 6.4 ± 5.6 <0.001***†††
    HOMA-β 83.4 ± 48.8 133.6 ± 88.6  161.9 ± 176.1 0.003**
    HbA1c 5.7 ± 0.4 6.0 ± 0.8 6.6 ± 1.3 <0.001†††
    hsCRP (mg/dL) 0.25 ± 0.44 0.27 ± 1.21 0.33 ± 0.42 <0.001†††
    FPG (mg/dL) 107.3 ± 23.3  107.5 ± 20.5  122.8 ± 44.1  0.030†
    FFA (mg/dL) 685.6 ± 269.8  608 ± 250.9  762 ± 694.5 0.036†
    TC (mg/dL) 189.3 ± 42.9  184.6 ± 42.3  185.4 ± 40.2  0.956
    TG (mg/dL) 100.2 ± 39.4  168.4 ± 102.1 169.6 ± 178.7 0.006**
    HDL-C (mg/dL) 58.1 ± 15.0 45.2 ± 10.9 45.4 ± 11.6 0.002**
    AST (U/L) 26.9 ± 8.3  32.1 ± 14.5 59.9 ± 31.8 <0.001†††
    ALT (U/L) 25.2 ± 14.3 41.3 ± 27.6 80.8 ± 55.2 <0.001*†††
    GGT (U/L) 52.2 ± 53.2 46.3 ± 43.6  76.6 ± 105.3 <0.001†††
  • As can be confirmed in Tables 1 and 2, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT) levels gradationally increased according to the histological severity of NAFLD in both the non-obese and obese groups.
  • Among the 361 subjects (mean age 53±14 years, male 48.5%), 295 had biopsy-proven NAFLD and 66 were healthy controls (no-NAFLD group). The no-NAFLD group had no clinical, biochemical, radiological, or histological evidence of fatty liver. Among the non-obese subjects, 82 had NAFLD and 48 were controls. In the obese group, 213 subjects had NAFLD and 18 were controls.
  • Based on BMI and liver histology findings (no-NAFLD, NAFL, and NASH), study subjects were classified into six groups: non-obese/no-NAFLD; non-obese/NAFL; non-obese/NASH; obese/no-NAFLD; obese/NAFL; and obese/NASH. In both the non-obese and obese groups, as the histological severity of NAFLD increased, the BMI, waist circumference, visceral adipose tissue (VAT) area, insulin resistance in adipose tissue (adipo-IR), insulin resistance (HOMA-IR), glycated haemoglobin (HbA1c), fasting plasma glucose, triglycerides (TG), HDL-cholesterol, the prevalence of diabetes mellitus, and the frequency of metabolic syndrome increased (Table 1).
    • Example 2: Serum Lipid Profiles Based on UPLC/QTOF-MS
  • The subjects with biopsy-proven NAFLD and BMI of less than 25 kg/m2 (“Boramae NAFLD cohort” (NCT 02206841)) were defined as non-obese NAFLD subjects. Controls were determined through liver biopsy during the evaluation on a living-donor liver transplant and confirmed to have no NAFLD through characterization of a solid liver mass suspected of liver adenoma or focal nodular hyperplasia based on abdominal image examination.
  • NAFLD was defined as the presence of 5% or more of macrovesicular steatosis identified via histological examination. NASH was diagnosed based on histological criteria of NASH-clinical research network (CRN): an overall pattern of histological hepatic injury consisting of steatosis, lobular inflammation, ballooning, or fibrosis was graded according to the NAFLD activity storing system.
  • The visceral adipose tissue (VAT) area was measured for quantification of visceral adipose amounts. Systemic insulin resistance (HOMA-IR) and β-cell function (HOMA-β) were evaluated using HOMA-B, and the insulin resistance in adipose tissue (adipo-IR) was also calculated. The metabolic syndrome was defined by the national cholesterol education program adult treatment panel III (NCEP ATP III) criteria.
  • The sera of 361 study subjects were analyzed for global lipid profiling by UPLC/Q TOF-MS, and 224 lipid metabolites were identified using several authentic standards and online databases, such as the human metabolome database (HMDB, www.hmdb.ca), METLIN (https://metlin.scripps.edu), and LIPID MAPS (www.lipidmaps.org).
  • High-performance liquid chromatography (HPLC)-mass spectrometry (MS)-grade solvents for ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC/QTOF-MS) analysis were purchased from Thermo Fisher Scientific (Waltham, Mass.). Ammonium acetate and lipid standards were purchased from Sigma-Aldrich (St. Louis, Mo.).
  • Lipidomic profiles of all lipid classes include: free fatty acids (FFA); glycerolipids (diacylglycerol (DAG) and triacylglycerol (TAG)); glycerophospholipids (lysophosphatidic acid (LPA), lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylinositol (PI); and sphingolipids (ceramide (Cer) and SM). Fold changes of lipid species in NAFL vs no-NAFLD and NASH vs NAFL for non-obese and obese patients are presented in FIG. 1.
  • As can be confirmed in FIG. 1, several lipid species, such as DAG, TAG, and SM, showed characteristic change patterns according to the histological severity of NAFLD in non-obese and obese adult NAFLD patients.
  • Especially, in the obese group compared with the non-obese group, the ratios of blood glycerolipid levels (concentrations) in NAFL to normal liver (no-NAFLD) were significantly higher, but the ratios in NASH to NAFL showed no significant differences. As for some specific saturated SMs, the ratios of blood SM levels in NAFL to normal liver (no-NAFLD) and the ratios of blood SM levels in NASH to NAFL were significantly high only in the non-obese group, but showed no significant differences in the obese group.
  • These data can confirm that in the obese group, the blood glycerolipids play an important role in the occurrence of non-alcoholic fatty liver, but play no great role in the progression to NASH or, rather, triacylglycerol serves as a preventive protective role.
  • However, in the non-obese group, specific saturated SMs play a significant role in not only the occurrence of nonalcoholic fatty liver but also the progression to NASH, but these features could not be confirmed in the obese group.
    • Example 3: DAG and TAG Changes Depending on NAFLD Severity
  • 50 μL of each serum sample was mixed with 500 μL of chloroform/methanol (2:1, v/v). After centrifugation at 13,000 rpm for 20 min at 4° C., 300 μL of the lower lipid phase was collected, and the solvents were removed under a gentle nitrogen stream at room temperature. The dried extracts were reconstituted in 250 μL of an isopropanol/acetonitrile/water mixture (2:1:1, v/v/v). After centrifugation at 13,000 rpm for 10 min at 4° C., the supernatants were transferred to vials for lipidomic analysis using UPLC (ACQUITY™ UPLC system, Waters, Manchester, UK) coupled with quadrupole time-of-flight mass spectrometry (QTOF-MS), and measured using QTOF-MS.
  • The column oven and auto-sampler temperatures were maintained at 40° C. and 4° C., respectively. The samples were eluted and separated using an Acquity UPLC BEH C18 column (2.1 μm×1.7 mm particles, Waters). The LC mobile phase was composed of 10 mM ammonium acetate in an acetonitrile/water mixture (4:6, v/v) (solvent A) and 10 mM ammonium acetate in an acetonitrile/isopropanol mixture (1:9, v/v) (solvent B). Gradient elution began with 40% B, increased to 65% B after 5 min, and then continuously increased until the composition of B was 99% by 10 min.
  • The composition was held at 99% B for 2 min. The resultant composition was returned to initial conditions after 17 min and was finally maintained for 3 min until equilibration. The flow rates were set to 350 μL/min. Five microliters of lipid extracts were injected into the UPLC/QTOF-MS system.
  • All samples were pooled in equal amounts to generate a quality control (QC) sample. Solvent blanks and QC sample injections were carried out between every 12 samples to assess analytical reproducibility. Positive and negative ionization modes were applied to each sample by using a hybrid QTOF instrument and a Triple TOF 5600 (AB Sciex, Concord, Canada) fitted with a DuoSpray ion source. The mass range was set to m/z 50-1500.
  • The following parameters were used for operation: ion spray voltage of 5500 V, source temperature of 500° C., a nebulizer pressure of 50 psi, a drying gas pressure of 60 psi, curtain gas of 30 psi, declustering potential of 90 V, and information-dependent acquisition (IDA) was used to acquire MS/MS spectra for ions.
  • To obtain the MS/MS spectra, the collision energy and collision energy spread were adjusted as 40 V and 15 V, respectively. The mass accuracy was maintained with an automated calibrant delivery system (AB Sciex) interfaced with the DuoSpray ion source. Lipid metabolites were identified according to available information (accurate mass, fragment ions, and/or retention time) that matched data from online databases (DBs; HMDB, METLIN, LIPID MAPS) and standard compounds.
  • Distinctive increases in glycerolipids including DAG and TAG species were observed in both the non-obese and obese groups, with a stepwise increase from NAFL to NASH. The differences in DAG and TAG levels with acyl chain lengths, degrees of desaturation, fold changes, and p-values were visualized using bubble plots.
  • The bubble plots illustrated the correlations among the chain length, degree of desaturation, fold change, and p-value of DAG and TAG through the comparison of histological subgroups. The y-axis represents the degree of desaturation, and the position of the bubbles relative to the x-axis corresponds to the chain length. The color of the bubbles indicates the fold change, and the size of the bubbles represents p-values that were obtained in the Mann-Whitney U-test with the Bonferroni correction.
  • As can be confirmed in FIG. 2A, the changes in DAG levels showed distinctive patterns among various histological subgroups. The levels of DAGs with relatively short chains and low degrees of desaturation statistically increased in NAFL vs NAFLD, regardless of obesity. In contrast, the levels of DAGs with long chains and high degrees of desaturation significantly decreased in NASH vs NAFL for the obese group.
  • As can be confirmed in FIG. 2B, the changes in TAG levels showed a trend similar to those in DAG levels. The statistical significance and fold change were weakened, but the chain length and the degree of desaturation were slightly changed.
  • The glycerolipids including DAG and TAG species exhibited distinctive change patterns that were affected by the length and desaturation degree of acyl chains. Moreover, the pattern of glycerolipid changes based on the histological severity was different between the non-obese and obese groups. Resultantly, the fold changes of circulating DAGs and TAGs classified based on histological severity were greater in obese NAFLD subjects than non-obese NAFLD patients.
  • Especially, the ratios of blood glycerolipid levels (concentrations) in NAFL to normal liver (no-NAFLD) were significantly higher in the obese group compared with the non-obese group, but the ratios of levels in NASH to NAFL showed no great differences.
  • These results could confirm that in the obese group, the blood glycerolipids play an important role in the occurrence of nonalcoholic fatty liver, but no significant role in the progression to NASH, or, rather triacylglycerol, which is a biologically inactive substance, is a harmless lipid that serves as a preventive protection role.
    • Example 4: Changes in Metabolic Syndromes According to NAFLD Severity and Correlation of NAFLD Severity with Liver Tissue and Liver Histology
  • The differences in intensities of metabolic syndromes according to the histological severity of NAFLD were observed for both the non-obese and obese groups. Significant differences in bar graphs are indicated with asterisks (Mann-Whitney U-test with Bonferroni correction; * p<0.05, ** p<0.01, and *** p<0.001).
  • As can be confirmed in FIG. 3, the levels of saturated SMs, including SM d36:0, SM d38:0, and SM d40:0, markedly increased by at least 1.3-fold in the NAFL/no-NAFLD group in the non-obese group. In contrast, the levels of SMs containing a long-chain length of greater than 42 carbons decreased in NAFL/no-NAFLD group, regardless of obesity.
  • In the obesity group, the levels of saturated SMs, such as SM d34:0, SM d36:0, SM d38:0, and SM d40:0, significantly increased in NASH/NAFL, but were not significant in NAFL/no-NAFLD.
  • These differences in saturated SM levels associated with NAFLD severity and obesity were also confirmed by the correlations with metabolic risk factors and liver histology. Spearman's correlation heat maps show the correlation of metabolic risk factors or liver histology with the SM levels in the non-obese and obese groups. Statistical significance is indicated with asterisks (* p<0.05, ** p<0.01, and *** p<0.001) (visceral adipose tissue (VAT); glycated haemoglobin (HbA1c); insulin resistance in adipose tissue (adipo-IR): homeostasis model assessment of insulin resistance (HOMA-IR); homeostasis model assessment of β-cell function (HOMA-β); and lobular inflammation (LI)).
  • As can be confirmed in FIG. 4, the levels of SM d36:0, SM d38:0, and SM d40:0 were significantly positively correlated with the VAT area, adipo-IR, and HOMA-IR in the non-obese group and were positively correlated with adipo-IR and HOMA-IR in the obese group. Furthermore, saturated SM levels were strongly correlated with the severity of steatosis, ballooning, and lobular inflammation in the non-obese group. However, only the steatosis was positively correlated with saturated lipid levels and amounts in the obese group.
  • Next, it was examined whether the levels of saturated SM species, including SM d36:0, SM d38:0, and SM d40:0, were altered by the presence and severity of steatosis and lobular inflammation. The intensities of SM d36:0, SM d38:0, and SM d40:0, steatosis (A; 0-3), lobular inflammation (B; 0-3), and ballooning (C; 0-2), but there were no fibrosis stages (D; 0-4) in non-obese subjects. Data are expressed as the means±standard deviation. Statistical significance is indicated with asterisks (Jonckheere-Terpstra test, *p<0.05, ** p<0.01, and *** p<0.001).
  • As can be confirmed in FIG. 5, as seen on the heat maps, the levels of saturated SMs markedly increased depending on the severity of steatosis, lobular inflammation, ballooning, and fibrosis according to grades thereof, especially in the non-obese patients. However, the saturated SM levels in the obese patients showed no stepwise increase with respect to the measurement of the histological severity of NAFLD except for the measurement of grades of steatosis. The fibrosis stage also had no stepwise association with the saturated SM levels regardless of obesity.
  • The saturated SM levels were further useful in improving diagnostic performance of NAFL and NASH in non-obese patients rather than obese NAFL and NASH, thereby preventing liver biopsy especially unnecessary for non-obese adult NAFLD patients.
    • Example 5: Predicting NAFLD Using Circulating Saturated SM Levels
  • To predict the histological severity of NAFLD by evaluating the diagnostic performance of combinations of the saturated SM levels (SM d36:0, SM d38:0, and SM d40:0), AUROCs with 95% CI were classified into the non-obese and obese groups and presented in Table 3 and FIG. 6.
  • TABLE 3
    ROC for Area Error p-value 95% CI Sensitivity Specificity
    Non-obese
    S1 0.644 0.062 0.025 0.522-0.766 56% 56%
    S2 0.789 0.057 <0.001 0.677-0.900 74% 73%
    S3 0.868 0.046 <0.001 0.778-0.959 84% 81%
    LI
    1 0.613 0.052 0.038 0.511-0.715 55% 55%
    LI
    2 0.812 0.082 0.001 0.651-0.973 75% 75%
    B1 0.726 0.045 <0.001 0.637-0.815 69% 68%
    B2 0.793 0.148 0.088 0.503-1.000 67% 67%
    Obese
    S1 0.679 0.072 0.022 0.538-0.820 57% 56%
    S2 0.67 0.067 0.026 0.538-0.803 56% 56%
    S3 0.809 0.057 <0.001 0.697-0.920 72% 72%
    LI
    1 0.561 0.051 0.245 0.461-0.662 57% 57%
    LI
    2 0.666 0.067 0.023 0.534-0.798 64% 65%
    B1 0.613 0.043 0.007 0.528-0.698 59% 57%
    B2 0.643 0.066 0.117 0.513-0.772 58% 57%
  • As can be confirmed in FIG. 6A, in the non-obese group, the AUROCs for steatosis 1, 2, and 3 (S1-S3) were 0.644, 0.789, and 0.868, respectively. In the obese group, the AUROCs for S1, S2, and S3 were 0.679, 0.670, and 0.809, respectively.
  • As can be confirmed in FIG. 6B, as for lobular inflammation, in the non-obese group, the AUROCs for lobular inflammation were 0.613 (score 1) and 0.812 (score 2), and in the obese group, the AUROCs were 0.561 and 0.666.
  • As can be confirmed in FIG. 6C, as for ballooning, in the non-obese group, the AUROCs for ballooning were 0.726 (score 1) and 0.793 (score 2). In the obese group, the AUROCs for scores 1 and 2 were 0.613 and 0.643, respectively.
  • In general, the ROC curves based on the histological severity in the non-obese group showed significantly high AUROCs compared with the obese group.
  • As can be confirmed in FIG. 7, to effectively discriminate subjects with NASH or NAFL from patients without NAFLD, the AUROCs were adjusted using combinations of AST, ALT, and GGT levels (model 1) or combinations of saturated SM levels (SM d36:0, SM d38:0, and SM d40:0) with AST, ALT, and GGT levels (model 2). P-values for pairwise comparison of AUROCs were provided using DeLong test.
  • TABLE 4
    ROC for Area Error p-value 95% CI Sensitivity Specificity
    Combinations of AST, ALT, and GGT
    Non-obese
    0 vs. 1 0.720 0.051 <0.001 0.619-0.821 65% 67%
    0 vs. 2 0.823 0.049 <0.001 0.726-0.919 77% 77%
    1 vs. 2 0.796 0.053 <0.001 0.693-0.899 77% 75%
    Obese
    0 vs. 1 0.785 0.061 <0.001 0.665-0.906 73% 72%
    0 vs. 2 0.928 0.029 <0.001 0.871-0.986 84% 83%
    1 vs. 2 0.836 0.027 <0.001 0.783-0.890 78% 76%
    Combinations of saturated SMs (SM d36: 0, SM d38: 0,
    and SM d40: 0), AST, ALT, and GGT
    Non-obese
    0 vs. 1 0.833 0.04 <0.001 0.753-0.914 73% 73%
    0 vs. 2 0.914 0.031 <0.001 0.852-0.976 84% 83%
    1 vs. 2 0.808 0.051 <0.001 0.709-0.907 68% 69%
    Obese
    0 vs. 1 0.781 0.06 <0.001 0.663-0.899 76% 78%
    0 vs. 2 0.96 0.022 <0.001 0.916-1.000 90% 89%
    1 vs. 2 0.837 0.027 <0.001 0.784-0.889 77% 75%
  • As can be confirmed in Table 4, in the non-obese group, the AUROCs for models 1 and 2 with comparison of NAFLD and NAFL were 0.720 and 0.833 (p=0.011 for AUROCs comparison). When the serum saturated SMs were added to serum AST, ALT, and GCT combinations, the diagnostic performance for distinguishing NASH from NAFL was significantly improved in the non-obese group.
  • The AUROCs for models 1 and 2 with comparison of NAFLD and NASH were 0.823 and 0.914 (p=0.033 for AUROCs comparison). The AUROCs for models 1 and 2 with comparison of NAFLD and NAFL were 0.785 and 0.781 (p=0.866 for AUROCs comparison). The AUROCs for models 1 and 2 with comparison of NAFLD and NASH were 0.928 and 0.960 (p=0.059 for AUROCs comparison).
    • INDUSTRIAL APPLICABILITY
  • The present disclosure relates to a method for providing information on diagnosis or prognosis determination of the histological severity of nonalcoholic fatty liver disease and, more specifically, to a method for identifying the increase or decrease of the risk associated with the severity of nonalcoholic fatty liver disease by measuring the levels of saturated sphingomyelins.

Claims (6)

What is claimed is:
1. A method for providing information on diagnosis or prognosis determination of histological severity of nonalcoholic fatty liver disease (NAFLD), the method comprising a measurement step of measuring the level of a sphingomyelin (SM) in a biological sample isolated from a subject.
2. The method of claim 1, wherein the sphingomyelin is a saturated sphingomyelin.
3. The method of claim 2, further comprising a risk determination step of determining that the risk associated with the severity of nonalcoholic fatty liver disease of the subject increases when the level of the saturated sphingomyelin in the measurement step is at least 1.3-fold compared with a normal control sample.
4. The method of claim 1, wherein the subject has a body mass index (BMI) of less than 25.
5. The method of claim 1, wherein the subject is an Asian.
6. The method of claim 1, wherein the biological sample is a serum or plasma.
US17/283,058 2018-10-26 2019-10-24 Method for providing information on diagnosis or prognostic measurement of histological severity of nonalcoholic fatty liver disease Pending US20210349110A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020180129190A KR102105880B1 (en) 2018-10-26 2018-10-26 Methods for providing information about the diagnosis of histologic severity or prognostic measurement of nonalcoholic fatty liver disease
KR10-2018-0129190 2018-10-26
PCT/KR2019/014084 WO2020085820A1 (en) 2018-10-26 2019-10-24 Method for providing information on diagnosis or prognostic measurement of histological severity of nonalcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
US20210349110A1 true US20210349110A1 (en) 2021-11-11

Family

ID=70332115

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/283,058 Pending US20210349110A1 (en) 2018-10-26 2019-10-24 Method for providing information on diagnosis or prognostic measurement of histological severity of nonalcoholic fatty liver disease

Country Status (6)

Country Link
US (1) US20210349110A1 (en)
EP (1) EP3872495A4 (en)
JP (1) JP7111906B2 (en)
KR (1) KR102105880B1 (en)
CN (1) CN113711047A (en)
WO (1) WO2020085820A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180275151A1 (en) * 2015-09-30 2018-09-27 One Way Liver, S.L. Metabolomic signature of diagnosis and disease progression in non-alcoholic fatty liver disease (nafld)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0715402A2 (en) * 2006-08-08 2013-11-26 Lipomics Technologies Inc MARKERS OF NON-ALCOHOLIC FATTY DISEASE (NAFLD) AND NON-ALCOHOLIC STETETHEPATITIS (NASH) AND METHODS OF USE
BR112012031232A2 (en) * 2010-06-10 2016-10-25 Metanomics Health Gmbh method, device and use
US20150011424A1 (en) * 2012-01-31 2015-01-08 Teknologian Tutkimuskeskus Vtt Method for determining liver fat amount and method for diagnosing nafld
WO2016081534A1 (en) * 2014-11-19 2016-05-26 Metabolon, Inc. Biomarkers for fatty liver disease and methods using the same
KR101787456B1 (en) * 2015-10-28 2017-10-18 한국화학연구원 The cancer stem cell biomarkers for diagnosis of non-alcoholic fatty liver disease and the therapeutics of liver cancer and disease
KR102292989B1 (en) * 2017-03-29 2021-08-26 재단법인 아산사회복지재단 Composition for preventing and treating nonalcoholic steatohepatitis by targeting S1PR4
KR20180129190A (en) 2017-05-25 2018-12-05 김명희 Foldable waterproof packing box

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180275151A1 (en) * 2015-09-30 2018-09-27 One Way Liver, S.L. Metabolomic signature of diagnosis and disease progression in non-alcoholic fatty liver disease (nafld)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
2017 *
Barr (J. Proteomes Res 2010 9:4501). (Year: 2010) *
Fan (Journal of Hepatology 2017 Vol. 67:862). (Year: 2017) *
Li (Eur J. Clin. Microbiol. Infect. Dis. 2014 33:1725). (Year: 2014) *
Tu (Scientific Reports 2017 7:6120). (Year: 2017) *

Also Published As

Publication number Publication date
WO2020085820A1 (en) 2020-04-30
JP2022502685A (en) 2022-01-11
KR102105880B1 (en) 2020-04-29
JP7111906B2 (en) 2022-08-02
EP3872495A4 (en) 2021-12-22
CN113711047A (en) 2021-11-26
EP3872495A1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
Zhou et al. Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites
Nezami Ranjbar et al. GC-MS based plasma metabolomics for identification of candidate biomarkers for hepatocellular carcinoma in Egyptian cohort
EP2546649B1 (en) Biomarkers for fatty liver disease and methods using the same
Roede et al. Serum metabolomics of slow vs. rapid motor progression Parkinson’s disease: a pilot study
US9423405B2 (en) Trimethylamine compounds as risk predictors of cardiovascular disease
Domínguez et al. Lipidomic profiling of endometrial fluid in women with ovarian endometriosis
Sun et al. Potential serum biomarkers and metabonomic profiling of serum in ischemic stroke patients using UPLC/Q-TOF MS/MS
JP5676275B2 (en) Markers for detecting oxidative stress, liver disease markers, and methods for testing pharmaceuticals
JP2018502286A (en) Biomarker for fatty liver disease and method of use thereof
Xiao et al. Identification of potential diagnostic biomarkers of acute pancreatitis by serum metabolomic profiles
Bai et al. Lipidomic alteration of plasma in cured COVID-19 patients using ultra high-performance liquid chromatography with high-resolution mass spectrometry
Gong et al. Discovery of metabolite profiles of metabolic syndrome using untargeted and targeted LC–MS based lipidomics approach
CN108027354B (en) Biomarkers for coronary heart disease
WO2017028312A1 (en) Biomarkers for coronary heart disease
Tokuoka et al. Isobaric mass tagging and triple quadrupole mass spectrometry to determine lipid biomarker candidates for Alzheimer's disease
Morris et al. Modulation of the lipidomic profile due to a lipid challenge and fitness level: a postprandial study
KR20170061704A (en) Methods for detecting ovarian cancer
Wolff et al. Sex differences in changes of protein synthesis with rapamycin treatment are minimized when metformin is added to rapamycin
JP2011232164A (en) Liver disease marker, method and device for measuring the same, and method for verifying medicine
López-López et al. Oxidized lipids in the metabolic profiling of neuroendocrine tumors–Analytical challenges and biological implications
Koike et al. Simultaneous determination of five bile acids as potential biomarkers for Alzheimer’s disease in mouse brain and plasma
Krishnan et al. Circulating metabolite biomarkers: A game changer in the human prostate cancer diagnosis
US8563318B2 (en) Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
KR20160124596A (en) Early Diagnosis of Diabetes and Cardiovascular Diseases Using Plasma Metabolites
US20210349110A1 (en) Method for providing information on diagnosis or prognostic measurement of histological severity of nonalcoholic fatty liver disease

Legal Events

Date Code Title Description
AS Assignment

Owner name: SEOUL NATIONAL UNIVERSITY HOSPITAL, KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KIM, WON;REEL/FRAME:055832/0036

Effective date: 20210406

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED